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Amyloid-b (Ab) is toxic to neurons and such toxicity is e at least in part e mediated via the NMDA
receptor. Calpain, a calcium dependent cystein protease, is part of the NMDA receptor-induced neuro-
degeneration pathway, and we previously reported that inhibition of calpain prevents excitotoxic lesions
of the cholinergic nucleus basalis magnocellularis of Meynert. The present study reveals that inhibition
of calpain is also neuroprotective in an in vivo model of Ab oligomer-induced neurodegeneration in rats.
Ab-induced lesions of the nucleus basalis induced a signiﬁcant decrease in the number of cholinergic
neurons and their projecting ﬁbers, as determined by analysis of choline-acetyltransferase in the nucleus
basalis magnocellularis and cortical mantle of the lesioned animals. Treatment with the calpain inhibitor
A-705253 signiﬁcantly attenuated cholinergic neurodegeneration in a dose-dependent manner. Calpain
inhibition also signiﬁcantly diminished the accompanying neuroinﬂammatory response, as determined
by immunohistochemical analysis of microglia activation. Administration of b-amyloid markedly
impaired performance in the novel object recognition test. Treatment with the calpain inhibitor,
A-705253, dose-dependently prevented this behavioral deﬁcit.
In order to determine whether pre-treatment with the calpain inhibitor is necessary to exhibit its full
protective effect on neurons we induced Ab toxicity in primary neuronal cultures and administered
A-705253 at various time points before and after Ab oligomer application. Although the protective effect
was higher when A-705253 was applied before induction of Ab toxicity, calpain inhibition was still
beneﬁcial when applied up to 1 h post-treatment.
We conclude that inhibition of calpains may represent a valuable strategy for the prevention of Ab
oligomer-induced neuronal decline and associated cognitive deterioration.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
According to the amyloid-b-hypothesis of Alzheimer’s disease
(AD) accumulation of Ab in brain parenchyma e possibly in its
soluble form e causes a degeneration of neurons and their
processes in brain areas involved in memory formation (Selkoe,
2008). Among the ﬁrst regions to be affected are the hippo-
campus and the nucleus basalis of Meynert. The latter provides the
majority of cholinergic input to neocortical structures and plays anx: þ49 621 589 3232.
immrich).
All rights reserved.essential role in attention and information storage (Blokland, 1995;
Van der Zee and Luiten, 1999). Damage and the selective degener-
ation of the nucleus basalis of Meynert provide the morphological
correlate of the cortical cholinergic deﬁciency in AD. The loss of this
discrete cholinergic neuronal population leads to an impairment of
higher cortical functions, which is directly related to the progres-
sive deterioration of memory and attention, and cognitive
processes in affected patients.
A number of studies suggest that Ab-induced toxicity in AD is
caused by excessive glutamate stimulation, over activation of the
NMDA receptor, and subsequent calcium accumulation in the
postsynaptic neuron (Harkany et al., 2000; Molnár et al., 2004;
Mattson et al., 2000). Recently, the pathology of Ab has been
Fig. 1. Schematic outline of the experimental setup for the in vivo experiments. Rats
received in total 6 intraperitoneal injections of the calpain inhibitor A-705253 or
saline. The ﬁrst injection was given 1 h prior to unilateral Ab lesions into the nucleus
basalis magnocellularis, the other 5 injections followed within two consecutive days
after the lesion. From the fourth day on (after the lesion) the rats were subjected to
different behavioral tests. Ten days after the lesion the animals were transcardially
perfused and the brains removed for immunohistochemical analysis.
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and Selkoe, 2007), and studies indicate an involvement of the
NMDA receptor also in oligomer toxicity (Shankar et al., 2007).
Although the exact mechanism of this process is not fully under-
stood, there is evidence that calpains, Ca2þ-dependent cystein
proteases, are components of the downstream cascade. Inhibition
of calpains prevents excitotoxic neuronal cell death in vitro (Caba
et al., 2002; Ray et al., 2006) and in vivo (Chiu et al., 2005;
Takano et al., 2005), and there is evidence that calpain cleaves
several downstream targets that are critical for the progression of
excitotoxic neurodegeneration (Hou et al., 2006; Wu et al., 2004).
Calpains have therefore been discussed as a target for interference
in the neurodegenerative diseases that are associated with
neuronal loss (for review see Huang and Wang, 2001; Goll et al.,
2003; Zatz and Starling, 2005).
Using a speciﬁc low molecular weight inhibitor, A-705253
(Lubisch et al. 2003), we have recently shown that inhibition of
calpain completely prevents NMDA-induced excitotoxic lesions of
the nucleus basalis magnocellularis (NBM), the rat analog of the
nucleus basalis of Meynert in humans. A-705253 also fully pro-
tected from behavioral deﬁcits that accompany such lesions
(Nimmrich et al., 2008). Although excitotoxicity is likely to
contribute to the pathology of AD, this study did not reveal whether
neuronal decline could also be prevented, if the insult was induced
by Ab. To provide this missing link we assessed whether calpain
inhibition would protect from Ab-induced degeneration of the
NBM, and whether such treatment would protect from associated
cognitive decline of the rats.
As oligomeric Ab is now thought to underlie the pathology of
the disease, we generated Ab-oligomers in vitro and used such
oligomer preparation e rather than the monomeric peptide e to
induce NBM degeneration in rats. Lesioning of the NBM causes
a decline of cholinergic projections, mimicking the characteristic
loss of forebrain cholinergic innervation in AD (Bartus et al., 1982;
Gaykema et al., 1992).
Here we present data showing that calpain inhibition prevents
Ab oligomer-induced neurodegeneration of NBM and associated
decrease of cortical cholinergic innervation. Furthermore, calpain
inhibition attenuates cognitive deﬁcits that occur as a result of such
neurodegeneration.
NMDA receptor activation is an early step in the excitotoxicity
cascade, and compounds targeting the NMDA receptor have to be
administered in close time proximity of the toxic stimulus. Calpain
activation lies further downstream in this cascade, thus offering an
opportunity to interfere with cell death signaling at later time
points. We therefore added to this study an in vitro analysis of the
time course of the calpain application relative to the point of insult.
Calpain inhibition is also neuroprotective when initiation of the
toxic insult has already been initiated.
2. Materials and methods
2.1. Calpain inhibitor
Calpain inhibitor A-705253 was solubilized in DMSO (SigmaeAldrich, St. Louis,
USA) and stored as 1 M stock at -20 C. Working stock solutions with different
concentrations of A-705253 were prepared in ultrapure water containing 0.9%
sodium chloride with a pH between 5 and 5.5. The solution was prepared freshly
before use.
2.2. Preparation of Ab-oligomers
Oligomeric Ab42 was prepared aswas described by Dahlgren et al. (2002). In short,
solid Ab42 peptide (EZBiolabs, Carmel, USA) was dissolved in 1,1,1,3,3,3-hexaﬂuoro-2-
propanol (HFIP) (SigmaeAldrich, St. Louis, USA) to a concentration of 1 mM. The
peptide solution was aliquoted and the HFIP removed by evaporation in a SpeedVac
(Savant Instruments, Hyderabad, India). The dry peptide ﬁlms were stored at 20 C
until further processing. Before use Ab42 ﬁlms were dissolved in anhydrous DMSO to5 mM and subsequently diluted in neurobasal medium to a ﬁnal concentration of
100 mM (stock solution). The stock solution was incubated at 4 C for 24 h to enable
Ab42 oligomerization.
2.3. Animals
All animals were purchased fromHarlan (Horst, The Netherlands). For the in vivo
experiments, we used male Wistar rats of 3.5 months of age. For the in vitro
experiments we used female C57BL/6J mice (12 weeks old). During the experiment
animals were kept under normal laboratory conditions in an air-conditioned room
(212 C) with a 12/12 h light dark cycle (lights on at 07.00 h) with food and tap
water ad libitum. All care and treatments were carried out in accordance with the
European Communities Council Directive on the use of experimental animals.
2.4. Nucleus basalis lesion
Surgery was performed as described in Luiten et al. (1995). The animals were
anaesthetized with Nembutal (sodiumpentobarbital, 60 mg/kg i.p.). The coordinates
for the injection in the nucleus basalis magnocellularis (NBM) were 1.5 mm poste-
rior to bregma, 3.2 mm lateral to midline as deﬁned by the atlas of Paxinos and
Watson (1986). A 5 mL Hamilton syringe was lowered into the brain, followed over
10 min by two injections of 0.5 mL of the freshly prepared solution of Ab1e42 oligo-
mers (250 pmol each) diluted in 0.01 mM phosphate buffer pH 7.4 unilaterally at
two dorsoventral positions, 6.0 mm and 6.7 mm ventral to the dura. The ﬁnal
injected amount of the peptide therefore was amounted to 500 pmol per animal. For
sham-operated animals two times 0.5 ml phosphate buffered physiological saline
solutionwere infused (0.01 mM pH 7.4 PBS) containing equivalent amount of DMSO,
which served for sham-injection. After each injection the needle was left in situ for
another 10 min to allow for diffusion and to limit spread of the solution during
withdrawal of the needle. Brain injections were performed only in the right hemi-
sphere and the left hemisphere was left undisturbed and served for the self-control
side for the histological examinations.
The animals received the calpain inhibitor A-705253 intraperitoneally in doses
of 1, 3, and 10 mg/kg of body weight, 1 h before, 12 h after and twice a day for two
consecutive days after surgery (for experimental design see Fig. 1).
2.5. Small open-ﬁeld behavior
Amoderate novelty-induced behavioral activation and habituation to a dimly lit
home-cage like novel environment was tested in this paradigm (Nimmrich et al.,
2008). The test also reﬂected the general behavioral condition after experimental
manipulations, since it was performed 3 days after the surgery. Every 10 s the
following behaviors were scored by behavioral sampling technique: a) rearing, b)
snifﬁng with head turning, c) walking, d) grooming, and e) immobility (resting).
Exploration was expressed by a combined score of rearing, snifﬁng and walking
(exploration¼ 3 rearingþ 1 snifﬁngþ 2walking scores). The representative
scores of each behavioral component were summed up in 5 min blocks and analyzed
statistically.
2.6. Novel object recognition
Testing the ability of rats to recognize a novel object in an otherwise familiar
environment represents a sensitive and discriminating test to assess memory
performance. Novel object recognition was measured in a conventional cylindrical
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surrounded by a 60 cm high reﬂective aluminum wall (Nyakas et al., 2009).
During the ﬁrst day the rats were allowed to habituate to the apparatus and their
open-ﬁeld behavior was recorded for 3 min (conventional open ﬁeld). The test was
carried out the day following to the 3 min open-ﬁeld test and consisted of 2 sessions.
During the 1st session the rats were allowed to explore in the open-ﬁeld apparatus
for 5 min while two identical objects (AþA) were placed into the arena. During the
2nd session, carried out 2.5 h after the 1st session, one of the two objects was
replaced by a novel one (BþA). The ratio of visiting the novel versus known objects
indicated the object recognition ability, i.e. attention behavior. The number and the
period in sec spent with exploration of the objects during the 1st and 2nd sessions
were recorded. The recognition ability of the novel object at the 2nd session was
calculated in the following way: duration of exploration of the novel (B) object was
divided by the duration of exploration of both novel (B) and familiar (A) objects and
expressed in percentage. The criterion to pass the test was that both objects had to
be visited at least 5 times during the ﬁrst session representing sufﬁcient interest for
object exploration. From the 57 animals only one failed to perform the test, thus
statistical analysis was conducted on 56 animals.
2.7. Brain tissue processing
At postoperative day 10 the animals were transcardially perfused under deep
pentobarbital anesthesia with a ﬁxative solution of 4% paraformaldehyde in 0.1 M
phosphate buffer pH 7.4 after a short pre-rinse with heparinized saline. The brains
were removed, post ﬁxed for two days in the same ﬁxative and stored in phosphate
buffer at 0 C, cryoprotected by 30% sucrose for 4 days and sectioned on a cryostat
microtome at a thickness of 20 mm. Vials processed for immunostaining contained
every 10th section at the level of NBM, i.e. the serial sections positioned 200 mm
apart. Free ﬂoating brain sections were processed for immunocytochemical staining.
2.8. ChAT staining of cholinergic ﬁbers
Immunostaining procedure was applied to visualize choline-acetyltransferase
(ChAT) positive cholinergic neurons in NBM and their axon ramiﬁcations in the
target brain areas selecting parietal neocortex. Goat anti ChAT primary antibody
(AB144P, Lot: LV1359401; Chemicon International, Temecula, CA, USA) was used in
dilution 1:500. Biotinylated rabbit anti goat antibody and Vectastain ACB kit was
obtained from Vector Laboratories (CA, USA). The staining was completed with
nickel-enhanced diaminobenzidine (DAB) reaction in the presence of H2O2.
2.9. Microglial activation
Mouse anti rat integrin aM [CD11b] monoclonal antibody (CLB1512, Lot:
0604026553; Chemicon International, Temecula, CA, USA)was used as ﬁrst antibody
in a dilution rate of 1:1500 to recognize activated microglia. The biotinylated second
antibody and the ABC kit were obtained from Vector Labs (CA, USA, see above). DAB
reaction was enhanced by nickel ammonium sulfate.
2.10. Quantiﬁcation of cortical cholinergic innervation
2.10.1. Reduction in cholinergic ﬁber density and cholinergic neurons
The quantiﬁcation procedure for cholinergic ﬁber density in the parietal
neocortex was established in our laboratory and described in detail in a series of
previous publications (Horváth et al., 2000; Harkany et al., 2001; Dolga et al., 2009).
Brieﬂy, parietal neocortex which is topographically the target of afferent cholinergic
pathway from the NBM sites where the Ab42 oligomers were injected, was analyzed
for ChAT positive ﬁber density with a Quantimet 600HR (Leica, Germany) image
analysis program. The exact measurement took place in the superﬁcial sublayer of
the layer V cortical area representing the densest zone of cortical cholinergic
innervation. In addition we determined the number of ChAT positive neurons in the
NBM. Three brain sections were analyzed for each experimental animal and the
results were averaged. Percent surface area of positively stained ﬁbers against zero
background and number of positively stained neurons were computed in both sides
of the brain section. The ChAT positive ﬁber density and NBM cell count ipsilaterally
to the lesion was compared to the intact contralateral side and the percent decre-
ment was calculated as an indicator of cholinergic degeneration.
2.10.2. Magnitude of microglial reaction
The magnitude of microglial activation was quantiﬁed with by image analysis
measuring the extent of CD11b-immunoreactive microglia in a speciﬁc volume at
the level of the lesion site (total inﬁltration volume). Therefore, a series of positively
stained sections were used to reconstruct the extent of activation area. At each
section the surface area of core structure around the injection channel and the size
of inﬁltration area were measured with the Quantimet 600 system (Leica, Germany)
by means of manual delineation of the affected area. Based on these measurements
the total volume of the inﬁltrated brain area was computed: (x1þ x2þ.xn)$
200 mm; where ‘x’ was the cross-sectioned stained area in mm2 and 200 mmwas the
distance between two consecutive sections. The volume of affected brain area was
expressed in mm3.2.10.3. Primary cortical neuron culture
Primary cortical neurons were prepared from embryonic brains (E14) of C57BL/6J
mice. The cortices were carefully dissected, meninges were removed and the neurons
separated by trituration. Cells were plated on poly-D-lysine pre-coated plates at
a density of 1.2105 cells/well (96 well plates). Neurobasal medium supplemented
with 2% (v/v) B27-supplement, 0.5 mM glutamine, 1% (v/v) penicillin/streptomycin
was used as a culture medium. After 48 h neurons were treated with 10 mM cytosine
arabinoside for another 48 h to inhibit non-neuronal cell growth. Subsequently, the
medium was completely exchanged with fresh medium and after 6 days of in vitro
culture, the neurons were used for experiments.
2.10.4. Treatment of cells
The neuroprotective effect of A-705253 was assessed by incubating neurons
(cultured in 96 well plates) for 24 h with 25 mM or 50 mM oligomeric Ab in the
presence or absence of different concentrations of A-705253. After the treatment the
cell viability was determined by an MTT-assay. All treatments were performed in
triplicates and the experiments were repeated at least two times.
2.10.5. Determination of cell viability by MTT-assay
Neuronal viability was determined by the colorimetric MTT [3-(4,5-dime-
thylthiazol-2-yl-)2,5-diphenyltetrazolium bromide] assay as described previously
(Mosmann, 1983). 1.25 mg/ml MTT solution was added to each well of a 96 well
plate. After 2 h of incubation, cells were lysed in DMSO. The absorbance of each well
was measuredwith an automated ELISA plate reader (Bio-Rad, Munich, Germany) at
595 nm with a reference ﬁlter at 630 nm.
2.10.6. Statistics
The Statistica 8 package was applied for one-way ANOVA evaluation of the
results of independent groups which was followed by Dunnett post hoc t-test to
reveal differences between two selected groups. The level of p< 0.05 was accepted
as signiﬁcant. Data are presented as means S.E.M.
3. Results
3.1. A-705253 protects neurons against Ab-induced toxicity in vitro
To investigate the neuroprotective properties of A-705253 against
Ab-induced toxicity, we treated primary cortical neurons with
different concentrations (0.04e5 mM) of the calpain inhibitor and
challenged with 25 mM or 50 mM of oligomeric Ab42 for 24 h. Our
results show that the calpain inhibitor A-705253 in the present
condition protects primary cortical neurons against oligomeric Ab42.
Moreover, we found that concentrations in the range of 1 mM of A-
705253 in the current experimental setup aremost effective (Fig. 2A).
Furthermore, we were interested if the temporal dynamics of
the treatment is important for the neuroprotective effect. Therefore
we applied 1 mM A-705253 2 h and 1 h before, 1 h and 2 h after, or
together with the Ab42 challenge. We found that pre-treatment, or
simultaneous treatment of A-705253with Ab42 was fully protective
against Ab induced toxicity (Fig. 2B). Interestingly, when neurons
were treated 1 h after the insult, calpain inhibition still exerted
a signiﬁcant neuroprotective effect. However, application of the
compound could not prevent neuronal damage when applied 2 h
after the insult.
3.2. Calpain inhibition prevents Ab-induced degeneration of
cholinergic ﬁbers and neurons after lesion of the nucleus
basalis magnocellularis
Recently, we demonstrated that the inhibition of calpain can
protect cholinergic neurons against an NMDA-initiated excitotoxic
insult (Nimmrich et al., 2008). Although excitotoxicity is likely to
contribute to the pathology of AD, this study did not reveal whether
neuronal decline could also be prevented, if the insult was induced
by Ab.
To assess the sensitivity of cholinergic neurons to Ab-induced
toxicitywe injected oligomeric Ab42 into the NBM and quantiﬁed the
loss of cholinergic neurons and their cortical innervations that orig-
inate from the NBM (Fig. 3) (Gaykema et al., 1992). Cholinergic
neurons and ﬁbers were visualized with the cholinergic marker
Fig. 2. A) Neuroprotection was determined by co-incubating increasing concentrations
of calpain inhibitor A-705253 with 25 mM or 50 mM Ab42 for 24 h. B) The effect of the
time point of treatment relative to the insult was assessed by incubating primary
cortical neurons were with 1 mM A-705253 for 2 h and 1 h before, after or together
with 20 mM oligomeric Ab for 24 h. Cell viability determined by MTT-assay. Bars
indicate the mean cell viability in % relative to untreated controls S.E.M. (*p< 0.05 vs
untreated control and #p< 0.05 vs Ab only).
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Theﬁberdensitywasmeasured in the superﬁcial sublayer of the layer
V as described earlier (Horváth et al., 2000). The cholinergic ﬁber
density (Fig. 3A and B) and the number of neurons (Fig. 3C and D)
ipsilaterally to the lesionwas compared with the intact contralateral
side respectively. The percentage of ﬁber and neuronal loss in the
various experimental groups is summarized in Fig. 4. Injection of
oligomerized Ab42 into the NBM led to a loss of 40.6 2.3% in
cholinergic neurons, which is a 26.78% higher depletion compared to
sham-injection (Figs. 3C, D and 4A) and a concomitant decrease of
26.4 3.4% in cholinergic ﬁber density (18.03% compared to sham
injected control) in the cortex (Fig. 4B, C). Pre-treatment with 3 and
10 mg/kg of the calpain inhibitor A-705253 signiﬁcantly prevented
the Ab-induced cell death and cholinergic ﬁber loss, respectively. The
smallest dose of 1 mg/kg A-705253 was ineffective. The density of
cholinergic neurons and ﬁber innervation was not affected in sham-
treated animals, which received 10 mg/kg A-705253.3.3. Reduced microglia activation in A-705253 treated rats
In neurodegenerative diseases, microglial activation is an early
sign that often precedes neuronal death and sustained local
inﬂammatory responses. For that reason we determined the effect
of calpain inhibition on microglia activation. We calculated the
amount of CD11b-immunoreactive microglia, as a measure of brain
inﬂammation, in a speciﬁc volume at the level of the lesion site
(inﬁltration volume) (Fig. 5B). Injection of oligomerized Ab42
resulted in a strong activation of microglia at the infusion site
(Fig. 5C), which was signiﬁcantly reduced in animals treated with
3 mg/kg A-705253 as measured by CD11b expression (Fig. 5A).
3.4. Calpain inhibition as well as NBM lesion does not
affect explorative behavior in rats
We further examined whether drug treatment or the Ab-
induced NBM lesion had an effect on the explorative behavior of the
animals. Therefore, the rats were tested in a small open ﬁeld and
a conventional open-ﬁeld paradigm to asses explorative behavior.
Neither the drug treated nor the Ab-induced NBM lesioned animals
showed any signiﬁcant differences in behavior in the tested para-
digms. Analysis of the different ambulatory behaviors in the open-
ﬁeld tests, i.e. rearing walking, snifﬁng was not different from
sham-treated rats. Exploration time, immobility as well as time
spent grooming was also unaffected and reﬂects the behavior of
healthy animals in such a paradigm (Fig. 6 AeC).
3.5. A-705253 prevents Ab-induced memory deﬁcits
in a novel object recognition paradigm
Cholinergic neuronal projections from the NBM are well known
to directly modulate neocortical attentional andmemory functions.
The novel object recognition task is a learning task which depends,
in part, on proper neocortical information processing. In a previous
study we could show that a lesion of the NBM in rats leads to
attention and memory impairments in a novel object recognition
paradigm (Nimmrich et al., 2008). Therefore, we used this behav-
ioral test to investigate whether the preservation of cortical
cholinergic function by calpain inhibitor A-705253 can prevent the
cognitive deﬁcits induced by Ab-mediated lesion of the NBM.
The novel object recognition test sensitively assesses attention,
or discrimination ability between a novel object placed nearby to
a familiar one in a habituated environment. The Ab42-lesioned
group showed less attention towards the novel object as compared
to the controls treated with vehicle. The amyloid-injected and drug
treated groups performed all better than the lesioned control, and
even the dose of 1 mg/kg A-705253 was effective in preventing
Ab42-induced memory deﬁcits (see Fig. 6D).
4. Discussion
Soluble, oligomeric forms of Ab42 are increasingly associatedwith
the neuropathological mechanisms of AD.Whereas the toxicity of Ab
oligomers has been demonstrated inmultiple studies,mainly in vitro,
the mode of action of those peptide aggregates remains largely
unknown. However, a greater understanding of the underlying
process of amyloid toxicity is pressing in order to developmedication
that speciﬁcally interferes with the Ab-induced disease cascade. A
number of authors reporting in vitro studies have suggested that the
pathological effect ofAboligomers ismediatedby theNMDAreceptor
(Shankar et al., 2007; Kelly and Ferreira, 2006; De Felice et al., 2007),
and that over activation of the NMDA receptor should be considered
as a common principle for some major neurological diseases,
including AD (Lipton and Rosenberg, 1994; Harkany et al., 2000;
Fig. 3. Anatomical description of studying the cholinergic system after NBM lesion with oligomerized Ab1e42. The upper panel shows ChAT positive ﬁbers in the parietal neocortex
of the lesioned rat. A) Ab1e42-lesioned side B) ipsilateral control side. The Ab1e42-injection site in the NBM (dashed circle) is depicted in ﬁgure C) the intact ipsilateral NBM (dashed
circle) is shown in D).
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entry of calcium into the cell, which activates proteases that are
involved in cell death signaling. Calpain is a calcium-activated
cysteine protease that has been implicated to contribute to NMDA-
mediated excitotoxic cell death in various studies. For example,
inhibition of calpain is neuroprotective after NMDA-exposure in
hippocampal slice cultures (Caba et al., 2002). In vivo, calpain inhi-
bition reduces neurodegeneration in the rat retina after NMDA-
injection (Chiu et al., 2005). Calpain has therefore been discussed as
target for neurodegenerative disorders (Huang andWang, 2001; Zatz
and Starling, 2005; Saez et al., 2006). Using the speciﬁc calpain
inhibitor A-705253 we recently reported that inhibition of calpain
prevents NMDA-induced lesioning of the NBM in rats, whereas
physiological NMDA-cascades remained unaffected (Nimmrich et al.,
2008). However, although these studies suggested that calpain
inhibition can prevent excitotoxic neurodegeneration in various
in vitro and animal models, evidence that calpain inhibition could be
protective against Ab42 oligomer-induced neuronal deterioration
remained elusive.
The present study provides now evidence that calpain inhibition
is neuroprotective against Ab oligomer-induced cholinergic celllesion. Injection of oligomeric Ab to the nucleus basalis caused
a strong deterioration of cortical cholinergic projections leading to
deﬁcits in learning behavior. Behavioral decline was prevented by
application of the calpain inhibitor A-705253. The neuroprotective
effect of calpain inhibition was also shown by morphological
analysis. Cholinergic denervation in the parietal cortex and the
extent of microglia activation around the injection in the NBMwere
greatly attenuated by A-705253. The present ﬁndings expand
previous ﬁndings in animal models of excitotoxicity, and allow the
conclusion that inhibition of calpain is effective in vivo against
neurodegeneration triggered by oligomeric Ab. Interestingly, our in
vitro studies indicate that calpain inhibition is not only effective
when the compound is applied prior to the insult. Efﬁcacy of A-
705253 against Ab-induced cell damage was demonstratede albeit
less pronounced e up to 1 h after administration of Ab. This indi-
cates that the Ab-induced cell death cascadee once initiatedemay
not instantly kill the neuron, but requires some time until degen-
eration is irreversible. If this holds true also for other acute forms of
neurodegeneration, this could offer a promising avenue for the
treatment of acute neurodegenerative disorders. It is likely that
drugs targeting the NMDA receptor may only be effective up to the
Fig. 4. Cholinergic neurons in the NBM and their innervation of the parietal neocortex was measured in 6 groups of animals: vehicle-treated and sham-lesioned (Sham); sham-
lesioned injected with 10 mg/kg A-705253 (Shamþ 10 mg); vehicle-treated and Ab1e42-lesioned (Ab); Ab1e42-lesioned and injected with A-705253 in doses of 1 and 3 mg/kg
(labeled Abþ 1 or 3 respectively). A) Ab1e42-injection into the NBM resulted in decrease in cholinergic neurons. B) Decrease in cholinergic ﬁber density in the parietal neocortex
after sham-injection and in the cholinergic NBM region. Ab1e42-injection (Ab) increased the decline of cholinergic neurons and cortical innervation, which was not modulated by
the smallest dose of 1 mg/kg, but greatly attenuated at 3 mg/kg. *p< 0.01 vs. Sham; #p< 0.01 vs. Ab. C) Representative photomicrographs of cholinergic innervation of the parietal
neocortex. Quantitative measurement of ﬁber density was performed between the two arrows in the superﬁcial part of layer V. The scale bar represents 100 mm.
I. Granic et al. / Neuropharmacology 59 (2010) 334e342 339time of the insult. At least from studies on long-term potentiation
(LTP), a neurophysiological paradigm considered tomimic neuronal
memory processing, it is known that NMDA receptor-related
cascades cannot be reversed by NMDAR blockers once the cascade
is initiated. This could be the reason why patients suffering from
acute neurodegenerative processes do not beneﬁt from current
pharmacological treatment: the drug is administered once the
NMDAR-dependent cell death cascades have already started. Future
studies need to reveal whether inhibition of calpain is also effective
in vivo after NBM-lesioning, which is currently hampered by
the fact that the time of Ab diffusion to target cells cannot exactly be
determined. The time point of treatment, however, may be less
relevant for more chronic neurodegenerative diseases, like those
accompanying amyloidoses. In any case, calpain inhibitionmight be
superior to drugs targeting the NMDA receptor for another reason:
calpain inhibition does not affect physiological processes like LTP
(Nimmrich et al., 2008). Thus, it is likely that calpain inhibition does
not interfere with memory processes, but indeed contributes solely
to the prevention of cognitive deﬁcits. This is also indicated by the
fact that the highest dose of A-705253 did not impair rat memory in
several tasks (e.g. novel object recognition test) (Nimmrich et al.,
2008).
The compound used here was introduced by Lubisch and
co-workers (Lubisch et al., 2003) and does not affect caspases or
the proteasome (Ki calpain¼ 27 nM; Ki proteasome> 10,000 nM;
Ki caspases> 10,000 nM). Therefore, it is likely that the protec-
tive effects against Ab-oligomer toxicity are mediated by inhibi-
tion of calpain, and not by reducing proteasome or caspase
activity. The proteasome complex (Rubinsztein, 2006; Pan et al.,
2008) as well as caspases (Cribbs et al., 2004) potentiallycontribute to neurodegeneration, and a discrimination from
these targets mandatory. It is likely that A-705253 has fully
reached the target in our experiments as it rapidly penetrates
tissues, affecting its cellular target within minutes after perfusion
(Neuhof et al., 2003, 2004). It also effectively prevented Ab-
induced toxicity at doses previously shown to inhibit calpain
(Nimmrich et al., 2008). It should be noted that A-705253 also
inhibits other molecules like cathepsin B to some extend. We
therefore cannot fully exclude that at least some of the observed
protective effects may be attributed to mechanisms other than
calpain inhibition. In reverse, it is also possible that the reduction
of efﬁcacy at higher concentration is caused by inhibition of
other proteins. Future synthesis of more selective compounds is
highly desirable for dissecting the molecular components of
neuroprotection.
The model presented here reﬂects some essential hallmarks of
the AD pathology. The NBM is one of the early regions to be affected
during AD and the overall neuropathology in this model, including
cholinergic denervation and microglial activation, features much of
the pathology found in AD patients.
Beyond this, Ab oligomers e rather than amyloid plaques or
monomeric amyloid-b e are thought to underlie the neurotoxic
initiator of the disease. They occur in patients prior to plaque
formation and correlate much better with cognitive deﬁcits than
amyloid plaques. Ab oligomers have been extracted from brains of
AD patients and correlate well with the severity of the disease. Ab
oligomers are therefore e to the best of our knowledge e currently
the most appropriate conformation of b-amyloid to induce
pathology. The oligomer preparation used here has been intro-
duced by Stine and colleagues (Stine et al., 2003) and was shown to
Fig. 5. Extent of microglia activation after Ab1e42-injection decreased under treatment with A-705253. A) Representative photomicrographs show the extent of microglia activation
at the level of the brain injection site measured in 6 groups of animals: vehicle-treated and sham-lesioned (Sham); sham-lesioned injected with 10 mg/kg A-705253
(Shamþ 10 mg); vehicle-treated and Ab1e42-lesioned (Ab); Ab1e42-lesioned and injected with A-705253 in three different doses of 1, 3 and 10 mg/kg (labeled Abþ 1, 3 or 10
respectively). The volume of total microglia inﬁltration volume around the injections (PBS or oligomers) is shown in B) (*p< 0.05 vs. Sham and #p< 0.05 vs. Ab). C) High-
magniﬁcation image shows robust microglia reaction around lesion site (scale bar 100 mm).
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(Lambert et al., 1998; Trommer et al., 2005) and have been
demonstrated to exhibit their pathogenic action via the NMDA
receptor (Lacor et al., 2007). The preparation is similar in their
biophysical properties to brain derived Ab oligomers, underlining
their physiological relevance (Gong et al., 2003). In spite of all
similarities to AD it must be noted, however, that the experimental
model presented here involves a rather rapid decline of neurons
and thus differs from the slowly progressive neurodegeneration
observed in AD. It would be challenging to examine whether cal-
pain inhibition also prevents more chronic neurodegeneration
processes, which is currently only feasible in transgenic mouse
models. Most of these transgenic models, however, suffer from
a lack of neurodegeneration and decline of cholinergic ﬁbers.
Hence, it may be an adequate approach to combine the effect of
calpain inhibition on neurodegeneration in an acute in vivo model,
and the prevention of other deﬁcits e like synaptic decline e in
chronic mousemodels. The latter effects were explored by Battaglia
and colleagues using another, less speciﬁc calpain inhibitor, E64
(Battaglia et al., 2003), who showed that long-term (5 mo) intra-
peritoneal application of E64 in APP(K670N/M671L)/PS1(M146L)
mice prevented synaptic impairment as measured by LTP. Chronic
calpain inhibition also attenuated the development of deﬁcits in
spatial behavior of these mice. Thus, it is likely that calpain inhi-
bition serves to protect from acute and chronic neuronal decline,
and from a variety of pathological features observed in AD.
Interestingly, protection from behavioral deﬁcits in our study is
more sensitive to calpain inhibition than the prevention ofcholinergic denervation and microglia activation. A signiﬁcant
improvement in cognitive function measured by novel object
recognition was already accomplished with 1 mg/kg of A-705253
whereas the best protection from Ab-induced cholinergic dener-
vation was achieved with a dose of 3 mg/kg. This did not further
improve with the highest dose of 10 mg/kg (data not shown). This
suggests that the efﬁcacy of calpain inhibitor A-705253 reaches
a plateau at 3 mg/kg in our in vivo model.
In addition, the highest dose (10 mg/kg) A-705253 did not
signiﬁcantly prevent microglia activation. This could indicate that
neither cholinergic denervation nor microglia activation do fully
contribute to the behavioral outcomemeasured by the novel object
recognition test. It is very likely that the microglia reaction might
follow a different doseeresponse course, which might facilitate
other molecular pathways, speciﬁc for microglia independent from
functional changes behind the behavioral effects.
Whether the effect on behavior at 1 mg/kg may be due to an
improvement of physiological function (and hence remain unde-
tected by neuroanatomical analysis) should be assessed in further
studies. Recent data showing the involvement of calpain in Ab-
mediated dysfunction of the synaptic vesicle machinery (Kelly
et al., 2005; Kelly and Ferreira, 2006) could support such view.
In summary the presented study add evidence that calpain inhi-
bition signiﬁcantly decreases acute Ab oligomer-induced degenera-
tion of NBM and its associated cholinergic ﬁber projections, and
attenuates behavioral deﬁcits associated with such lesions. Further-
more, in vitro data suggest that inhibition of calpain is still effective
when performed shortly after the insult. Our ﬁndings indicate that
Fig. 6. Behavioral activity was compared in a small open-ﬁeld paradigm. Exploration is expressed as a combined score of rearing, walking and snifﬁng in A), grooming is depicted in
B), and immobility is shown in C). Scores were collected by behavioral sampling every 10 s for 25 min. No statistical difference could be observed between the groups. Attention was
estimated by measuring novel object recognition ability in a habituated open ﬁeld. The results shown in D). Fifty percent performance means chance level since both the novel and
familiar objects are explored by equal amount of time. Ab1e42-lesioned and vehicle-treated rats performed signiﬁcantly worse than controls (Sham) (*p< 0.05; Dunnett post hoc
test). Treatment with different doses of A-705253 prevented the behavioral deﬁcit caused by Ab42-injection (#p< 0.05 vs. Ab).
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